RESEARCH-USE BIOSIMILAR ANTIBODY

Sarilumab

Monoclonal antibody · IgG1

Asahi Kasei Pharma CorpIgG1RUO

Sarilumab is a monoclonal antibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis.

TARGETAsahi Kasei Pharma Corp
YMonoclonal antibody
CATALOGSC-BS-185
CATALOG NUMBERSC-BS-185
MOLECULAR WEIGHTApprox. 144.12 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Sarilumab is a monoclonal antibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis.

Sarilumab is a recombinant research-use antibody directed against Asahi Kasei Pharma Corp.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Sarilumab | StellaCyte